Condition: Sickle Cell Disease · Sponsor: Robert Nickel
This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD).
This description comes directly from the study's public registry record.
Robert Nickel, MD · 202-476-5000 · RNickel@childrensnational.org
Maryanne Odinakachukwu · 202-476-2957 · modinakach@childrensnational.org
Always discuss trial participation with your own doctor first.
| Children's National Health System | Washington D.C., District of Columbia, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Columbia University | New York, New York, United States | Recruiting |
| Levine Children's Hospital | Charlotte, North Carolina, United States | Recruiting |
| Nationwide Children's Hospital | Columbus, Ohio, United States | Recruiting |
| Alberta Children's Hospital | Calgary, Alberta, Canada | Recruiting |
| The Hospital for Sick Children | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03587272